Table 3.
Comparison of clinical and laboratorial data between the normal and abnormal clusters
| Normal cluster |
Abnormal cluster |
p value |
|
|---|---|---|---|
| Number of patients | 39 | 11 | |
| IPSS score | |||
| Low / Intermediate-1 | 21 (55%) | 2 (18%) | |
| Intermediate-2 / High / MDS-AML | 17 (45%) | 9 (82%) | 0.031 |
| NA | 1 | ||
| WHO classification | |||
| <5% bone marrow blasts | 18 (46%) | 1 (9%) | |
| >5% bone marrow blasts | 16 (41%) | 8 (73%) | 0.027 |
| Chronic myelomonocytic leukemia | 5 (13%) | 2 (18%) | |
| Infection | 8 (21%) | 3 (27%) | 0.69 |
| History of transfusion | |||
| Yes | 24 (70%) | 7 (70%) | 0.67 |
| No | 10 (30%) | 3 (30%) | |
| NA | 5 | 1 | |
| Peripheral blood lymphocyte count (median) | 1410 | 1310 | 0.37 |
| WT1 expression (median) | 0.0062 | 0.034 | 0.047 |
| Bone marrow blasts at sample (median) | 2 | 10 | 0.056 |
| Peripheral blood lymphocyte count (median) | 1410 | 1310 | 0.37 |
| Bone marrow cellularity | |||
| Hypocellular | 6 (15%) | 3 (27%) | 0.4 |
| Normocellular / Hypercellular | 28 (71%) | 7 (63%) | |
| NA | 5 | 1 | |
| Previous Treatment | |||
| Growth Factor | 20 | 3 | 0.189 |
| 5’ Azacytidine | 4 | 6 | 0.004 |
| Anthi-thymocyte globulin | 3 | 0 | 0.4 |
| Thalidomide / lenalidomide | 7 | 1 | 0.66 |
| Cytotoxic Chemotherapy | 4 | 2 | 0.6 |